Table 1.
Participants demographic and clinical features.
| DN (n = 14) | HC (n = 14) | p Value | |
|---|---|---|---|
| Age(years) | 50.29 ± 10.29 | 48.93 ± 10.49 | 0.733 |
| Gender(male/female) | 8/6 | 7/7 | 0.314 |
| oral hypoglycemic drugs(yes/no) | 4/10 | 0/14 | 0.031 |
| Insulin (yes/no) | 3/11 | 0/14 | <0.01 |
| Antibiotic use (yes/no) | 1/13 | 0/14 | 0.309 |
| Ghb(%) | 7.50(6.76,8.59) | 5.85(5.75,5.90) | <0.01 |
| Hb(g/L) | 105.58 ± 19.01 | 136.71 ± 13.99 | <0.01 |
| Count of NG (10^9/L) | 3.55 ± 1.24 | 3.26 ± 0.77 | 0.468 |
| Count of Leu (10^9/L) | 1.52 ± 0.70 | 1.95 ± 0.32 | 0.056 |
| 24h-Protein (g/24h) | 5.64(2.82,8.25) | 0(0,0) | <0.01 |
| TCR（g/g) | 3.84(2.03,8.92) | 0(0,0) | <0.01 |
| Blood glucose (mmol/L) | 5.53(4.41,7.96) | 4.98(4.82,5.11) | 0.227 |
| Urea (mmol/L) | 9.66(6.52,13.07) | 3.98(3.68,4.98) | <0.01 |
| Creatinine (μmol/L) | 226.64 ± 318.63 | 72.57 ± 20.92 | 0.094 |
| Uric acid (μmol/L) | 320.14 ± 70.63 | 281 ± 97.57 | 0.235 |
| eGFR (mL/min/1.73 m^2) | 56.07 ± 29.83 | 95.45 ± 12.48 | <0.01 |
| Alb (g/L) | 30.78 ± 6.36 | 46.5 ± 2.87 | <0.01 |
| CHO (mmol/L) | 4.6 ± 1.72 | 4.44 ± 0.84 | 0.762 |
| TG (mmol/L) | 1.55(1.05,2.34) | 1.04(0.62,1.51) | 0.164 |
| HDL (mmol/L) | 1.4 ± 0.33 | 1.15 ± 0.48 | 0.123 |
| LDL (mmol/L) | 3.06(1.56,3.82) | 2.84(1.98,3.24) | 0.635 |
| DM course (months) | 120(99,180) | 0(0,0) | <0.01 |
| Hypertension history (months) | 18(1.62,66) | 0(0,0) | <0.01 |
| CD history (months) | 0(0.27) | 0(0,0) | 0.21 |
| CI course (months) | 0(0,0) | 0(0,0) | 0.769 |
| DR (positive/negative) | 0/6 | / | / |
Ghb: glycosylated hemoglobin; Hb: hemoglobin; NG: neutrophilic granulocyte; Leu: leukocyte; TCR: urine total protein and creatinine ratio; eGFR: estimated glomerular filtration rate; Alb: serum albumin; CHO: cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; DM: diabetes mellitus; CD: cardiovascular disease; CI: cerebral infarction; DR: diabetic retinopathy.